相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms
Vibe Skov et al.
LEUKEMIA & LYMPHOMA (2017)
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Ilyas Chachoua et al.
BLOOD (2016)
Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera
Caroline H. Riley et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
CRT AM determines the CD4+ cytotoxic T lymphocyte lineage
Arata Takeuchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2016)
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm
Jen Chin Wang et al.
LEUKEMIA RESEARCH (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
Lasse Kjaer et al.
PLOS ONE (2016)
Type I interferons in Bacterial infections: A Balancing Act
Pavel Kovarik et al.
FRONTIERS IN IMMUNOLOGY (2016)
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
Emmanuelle Verger et al.
BLOOD (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α
Caroline H. Riley et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Bruno Cassinat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis
Vibe Skov et al.
LEUKEMIA & LYMPHOMA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma
Alan P. Skarbnik et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
Caroline Hasselbalch Riley et al.
BLOOD (2011)
Response definition criteria for ELISPOT assays revisited
Z. Moodie et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Arginase: an emerging key player in the mammalian immune system
Markus Munder
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CD4 cells can be more efficient at tumor rejection than CD8 cells
Ainhoa Perez-Diez et al.
BLOOD (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
分享论文
